PHAT
Price:
$9.29
Market Cap:
$635.23M
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.[Read more]
Industry
Biotechnology
IPO Date
2019-10-25
Stock Exchange
NASDAQ
Ticker
PHAT
According to Phathom Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 476.96M. This represents a change of -34.66% compared to the average of 729.91M of the last 4 quarters.
The mean historical Enterprise Value of Phathom Pharmaceuticals, Inc. over the last ten years is 478.29M. The current 476.96M Enterprise Value has changed 9.87% with respect to the historical average. Over the past ten years (40 quarters), PHAT's Enterprise Value was at its highest in in the March 2021 quarter at 1.17B. The Enterprise Value was at its lowest in in the March 2018 quarter at 0.
Average
478.29M
Median
465.22M
Minimum
212.10M
Maximum
865.36M
Discovering the peaks and valleys of Phathom Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 159.24%
Maximum Annual Enterprise Value = 865.36M
Minimum Annual Increase = -40.64%
Minimum Annual Enterprise Value = 212.10M
Year | Enterprise Value | Change |
---|---|---|
2023 | 225.91M | -40.64% |
2022 | 380.59M | -40.15% |
2021 | 635.93M | -26.51% |
2020 | 865.36M | 57.38% |
2019 | 549.85M | 159.24% |
The current Enterprise Value of Phathom Pharmaceuticals, Inc. (PHAT) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
414.14M
5-year avg
531.53M
10-year avg
478.29M
Phathom Pharmaceuticals, Inc.’s Enterprise Value is less than Day One Biopharmaceuticals, Inc. (938.25M), less than Blueprint Medicines Corporation (6.39B), greater than Lyra Therapeutics, Inc. (25.33M), less than Cullinan Oncology, Inc. (639.85M), greater than Acumen Pharmaceuticals, Inc. (131.98M), greater than X4 Pharmaceuticals, Inc. (70.82M), greater than Inozyme Pharma, Inc. (196.95M), less than VectivBio Holding AG (848.58M), less than Kiniksa Pharmaceuticals, Ltd. (1.45B), less than Structure Therapeutics Inc. (1.82B), less than Karuna Therapeutics, Inc. (12.43B), greater than Immix Biopharma, Inc. (51.27M), greater than CNS Pharmaceuticals, Inc. (-790860.00), greater than Hepion Pharmaceuticals, Inc. (4.94M), greater than Freeline Therapeutics Holdings plc (2.82M), greater than AVROBIO, Inc. (-85302404.00), greater than Terns Pharmaceuticals, Inc. (290.07M), greater than Amylyx Pharmaceuticals, Inc. (265.24M),
Company | Enterprise Value | Market cap |
---|---|---|
938.25M | $1.36B | |
6.39B | $6.01B | |
25.33M | $13.81M | |
639.85M | $739.49M | |
131.98M | $135.18M | |
70.82M | $90.03M | |
196.95M | $174.73M | |
848.58M | $1.06B | |
1.45B | $1.54B | |
1.82B | $1.99B | |
12.43B | $12.60B | |
51.27M | $69.87M | |
-790860.00 | $6.15M | |
4.94M | $4.21M | |
2.82M | $28.28M | |
-85302404.00 | $5.24M | |
290.07M | $558.90M | |
265.24M | $334.51M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Phathom Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Phathom Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Phathom Pharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Phathom Pharmaceuticals, Inc. (PHAT)?
What is the 3-year average Enterprise Value for Phathom Pharmaceuticals, Inc. (PHAT)?
What is the 5-year average Enterprise Value for Phathom Pharmaceuticals, Inc. (PHAT)?
How does the current Enterprise Value for Phathom Pharmaceuticals, Inc. (PHAT) compare to its historical average?